EDIT (Editas Medicine) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EDIT Editas Medicine Inc EDIT
45 GF Score
Price $3.16
GF Value $1.82
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Editas Medicine Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

EDIT
45GF Score
Editas Medicine Inc EDIT
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Editas Medicine (EDIT) Overvalued in 2026?

Based on GuruFocus' analysis, Editas Medicine stock appears to be overvalued. The current stock price of $3.16 is trading 73.6% above its estimated GF Value™ of $1.82. GuruFocus considers Editas Medicine to be Significantly Overvalued.

Key valuation signals for EDIT:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: $1.82 vs. price of $3.16 (73.6% above fair value)
  • GF Score™: 45/100 with 8 warning signs

No single metric tells the full story. See the EDIT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Editas Medicine Business Description

Other Exchanges 0IFK:UK8EM:Germany
Address 11 Hurley Street, Cambridge, MA, USA, 02141
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
45GF Score

Get the complete analysis for EDIT

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.16
Price
$1.82
GF Value